Skip to content
Poster

Hepatoprotective effects of efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Background & Aim:

Efruxifermin (EFX, long-acting FGF21 analogue) is currently in phase-3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The present study aimed to investigate the therapeutic benefits of EFX on metabolic, biochemical, histopathological and transcriptome profile in the Gubra Amylin NASH (GAN) dietinduced obese (DIO) and biopsy confirmed mouse model of MASH with liver fibrosis.

Subjects
GAN DIO-MASH mouseMouseBody weightBioinformaticsMetabolic dysfunction-associated steatohepatitisFGF receptor-1EfruxiferminHistopathology scoreImage analysisImmunohistochemistry (IHC)Liver biopsyLiver morphometryNext-generation sequencingRNA sequencing

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top